| Name | Glimepiride |
| Description | Glimepiride (HOE-490) is a long-acting, third-generation sulfonylurea with hypoglycemic activity. |
| In vitro | In both normal and insulin-resistant adipocytes, as well as in myocytes, Glimepiride effectively stimulates glucose transport, and the synthesis of lipids and glycogen. In cardiomyocytes, Glimepiride (IC50=6.8 nM) inhibits the pinacidil-activated whole-cell K(ATP) current. Additionally, in HEK 293 cells, Glimepiride (IC50=6.2 nM) blocks the K(ATP) channels formed by the co-expression of Kir6.2/SUR2A subunits. |
| In vivo | Within diabetic rats, Glimepiride has been shown to decrease the incidence of sperm abnormalities, enhance sperm count, and bolster antioxidant capacity. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 16.67 mg/mL (33.98 mM), Sonication is recommended.
|
| Keywords | SUR2B | SUR2A | SUR1 | PotassiumChannel | Potassium Channel | Inhibitor | inhibit | HOE490 | HOE 490 | Glimepiride |
| Inhibitors Related | Minoxidil sulfate | Tannic acid | Hydrochlorothiazide | (±)-Naringenin | Tetraethylammonium bromide | Halothane | Butamben | Ursodeoxycholic acid | Cloperastine hydrochloride | Minoxidil | Nifedipine | Indapamide |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bitter Compound library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |
United States
